Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and genetic tests. Many genetic tests are not FDA approved usually called LDTs […]
Challenges Ahead But Sequencing Is A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum provided full day coverage offering insights as to how the science driving personalized medicine is reshaping […]
April Sell-Off Hit Diagnostic Small and Mid Caps The bursting of the biotech bubble affected many small cap growth stocks. 2013 was a great year for our portfolio so some weakness was expected after the huge Q1 2014 moves. Most of our picks peaked in Jan/Feb time frame when many of our favorites were hit […]
Rayno Life Science Focus Stocks: ARIA, IMGN, PCYC Ariad (ARIA) Abstracts Several data presentations will be made for Iclusig (Ponatinib) for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring key investigators and slide presentations will be held on June 2. Immunogen (IMGN) Abstracts The focus will be on […]
Rayno Life Science Stocks -Green Screen Rules-NASDAQ (4168) Up 1.16% Speculative ETF XBI (134.50) up 4.69% and 7.88% over 5 days; 52 week high $172.52. ETF PBE ($40.85) up over 3%. Momentum stocks are soaring but way off all time highs in February. Big Rayno Biopharma Movers: ACHN up 8%, ALKS up 3.4%, ARIA up […]
Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in immunology, oncology and infectious disease were being launched. The life science sector […]
